The identification of activating NOTCH1 mutations in T cell acute lymphoblastic leukemia (T-ALL) led to clinical testing of g-secretase inhibitors (GSIs) that prevent NOTCH1 activation 1-4 . However, responses to these inhibitors have been transient 5 , suggesting that resistance limits their clinical efficacy. Here we modeled T-ALL resistance, identifying GSI-tolerant 'persister' cells that expand in the absence of NOTCH1 signaling. Rare persisters are already present in naive T-ALL populations, and the reversibility of their phenotype suggests an epigenetic mechanism. Relative to GSI-sensitive cells, persister cells activate distinct signaling and transcriptional programs and exhibit chromatin compaction. A knockdown screen identified chromatin regulators essential for persister viability, including BRD4. BRD4 binds enhancers near critical T-ALL genes, including MYC and BCL2. The BRD4 inhibitor JQ1 downregulates expression of these targets and induces growth arrest and apoptosis in persister cells, at doses well tolerated by GSI-sensitive cells. Consistently, the GSI-JQ1 combination was found to be effective against primary human leukemias in vivo. Our findings establish a role for epigenetic heterogeneity in leukemia resistance that may be addressed by incorporating epigenetic modulators in combination therapy.
The identification of activating NOTCH1 mutations in T cell acute lymphoblastic leukemia (T-ALL) led to clinical testing of g-secretase inhibitors (GSIs) that prevent NOTCH1 activation [1] [2] [3] [4] . However, responses to these inhibitors have been transient 5 , suggesting that resistance limits their clinical efficacy. Here we modeled T-ALL resistance, identifying GSI-tolerant 'persister' cells that expand in the absence of NOTCH1 signaling. Rare persisters are already present in naive T-ALL populations, and the reversibility of their phenotype suggests an epigenetic mechanism. Relative to GSI-sensitive cells, persister cells activate distinct signaling and transcriptional programs and exhibit chromatin compaction. A knockdown screen identified chromatin regulators essential for persister viability, including BRD4. BRD4 binds enhancers near critical T-ALL genes, including MYC and BCL2. The BRD4 inhibitor JQ1 downregulates expression of these targets and induces growth arrest and apoptosis in persister cells, at doses well tolerated by GSI-sensitive cells. Consistently, the GSI-JQ1 combination was found to be effective against primary human leukemias in vivo. Our findings establish a role for epigenetic heterogeneity in leukemia resistance that may be addressed by incorporating epigenetic modulators in combination therapy.
T-ALL is an aggressive malignancy frequently associated with activating mutations in NOTCH1, a critical oncogene in this disease 1 . GSIs that prevent NOTCH1 cleavage and activation have been tested in clinical trials and mouse models, but responses have been modest and transient 5 . To understand the mechanisms by which T-ALL cells overcome NOTCH1 inhibition, we modeled GSI resistance in vitro and in vivo and investigated the functional and molecular characteristics of resistant cells. By chronically exposing NOTCH1-dependent human T-ALL cells to a GSI (compound E) in vitro, we isolated a population of persister cells that tolerated GSI concentrations more than 50-fold higher than the concentrations tolerated by naive cells (Fig. 1a,b and Supplementary Figs. 1a and 2a) .
To characterize these drug-tolerant cells, we first examined the active intracellular form of NOTCH1 (ICN1) 6 . ICN1 was present at high levels in naive T-ALL cells but was essentially undetectable in persister cells (Fig. 1c, top and Supplementary Fig. 2b , top). Expression of NOTCH1 target genes, including DTX1 and HES4, was also downregulated in persister cells ( Supplementary  Figs. 1b,c and 3i) . The phenotype was reversible, as persister cells rapidly re-expressed ICN1 and NOTCH1 target genes after removal of the GSI (Fig. 1c and Supplementary Figs. 1b,d and 2b) . Re-exposure of these 'reversed' cells to GSI led to downregulation of the expression of NOTCH1 target genes and growth arrest, as in the original naive T-ALL population (Supplementary Fig. 1b ). This reversibility suggests that the resistance phenotype is mediated epigenetically.
Induction of MYC is thought to be a major mechanism whereby constitutive NOTCH1 activation results in leukemic T cell transformation [7] [8] [9] . Although MYC protein levels were dramatically reduced by short-term GSI treatment, moderate levels were maintained in the persister cells, despite continued GSI treatment ( Fig. 1c and Supplementary Fig. 2b) . Consistently, the strong MYC transcriptional An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia signature of naive T-ALL cells was reduced in persister cells (Supplementary Table 1 ). Conversely, gene signatures associated with mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), phosphoinositide 3-kinase (PI3K) and mTOR signaling were enhanced (Supplementary Table 1 ). Genetic alterations of PTEN and consequent AKT pathway activation have been associated with GSI resistance 10, 11 . Although the T-ALL cells modeled here did not harbor PTEN mutations 11 , persister cells had higher levels of phosphorylated PTEN and were sensitive to AKT inhibitors ( Supplementary Figs. 1e  and 2d) . mTOR activation has also been observed in T-ALL 12, 13 . Persister cells had higher levels of p2481 (phosphorylated mTOR) and were sensitive to the mTOR inhibitor rapamycin (Fig. 1d,e and Supplementary Fig. 2c ). Inhibition of mTOR markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells (Fig. 1f) . In contrast, persister cells did not exhibit enhanced sensitivity to doxorubicin or vorinostat (Supplementary Figs. 1f and 2e) . These data suggest that rewired signaling programs maintain MYC expression and cell proliferation in the absence of NOTCH1 activity.
Next, we sought to determine whether resistance is induced by GSI treatment or whether, alternatively, a fraction of unexposed cells is already drug tolerant. In support of the latter hypothesis, when we isolated single cells from a naive T-ALL population, we found that ~4% expanded in the presence of GSI (Fig. 1g) . In contrast, the remaining cells failed to grow, even after extended periods of time. An analogous analysis of reversed cells, which were exposed to GSI but then expanded in the absence of drug for 1 month, again showed a small fraction of GSI-tolerant single cells (~9%). We hypothesized that pre-existing GSI-tolerant cells share phenotypic characteristics with persister cells, such as mTOR dependency. In support of this idea, pretreatment with rapamycin reduced the frequency of GSItolerant single cells by ~5-fold (Fig. 1g) . These data suggest that GSI resistance depends on a pre-existing subpopulation of T-ALL cells with distinct signaling programs that readily expand in the absence of NOTCH1 signaling. The reversibility of the phenotype suggests that this heterogeneity is mediated by epigenetic rather than genetic alterations.
In addition to altered signaling, persister cells exhibited morphologic changes, including decreased cell and nuclear sizes (Fig. 2a,b and Supplementary Fig. 3a,b) . We postulated that these changes might reflect global chromatin changes associated with NOTCH1 inactivity. We found that the persister cells had higher global levels of repressive histone modifications and heterochromatin protein 1 (HP1) (Fig. 2c,d and Supplementary Fig. 3c,e) . Chromatin in persister cells was also relatively inaccessible to micrococcal nuclease (MNase) digestion (Supplementary Fig. 3g ), consistent with a compact state. Chromatin compaction likely reflects the absence of NOTCH1 activity, as it was also evident in cells with short-term GSI treatment and in T-ALL cells in which NOTCH1 signaling was inhibited by dominant-negative mastermind-like 1 (DN-MAML1) ( Fig. 2c and Supplementary Figs. 1c and 3c,e,i) .
We postulated that the altered chromatin state in persister cells might uncover new susceptibilities that could be targeted by emerging epigenetic therapies. To test this hypothesis, we designed a lentiviral short hairpin RNA (shRNA) knockdown screen that targeted ~350 chromatin regulators with an average of 5 independent hairpins per gene (Online Methods). We identified ~15 genes for which knockdown compromised the survival of naive and persister cells, which were thus presumed to be generally required in T-ALL rapamycin pretreated, n = 858; pooled from 2 independent experiments; ***P < 0.001; error bars, s.d.). These data suggest that GSI tolerance is already evident in a small fraction of naive T-ALL cells and is reversible.
l e t t e r s npg l e t t e r s (Supplementary Table 2 ). We also identified genes preferentially required for the survival of either naive or persister cells. For example, naive cells were preferentially dependent on several histone deacetylases, whereas persister cells were more dependent on certain arginine methyltransferases and histone methyltransferases ( Fig. 2e and Supplementary Table 2 ).
We identified BRD4 as a top hit in the screen, with three shRNAs noticeably reducing the proliferation of persister cells without affecting the proliferation of the naive population ( Supplementary  Fig. 4a ,b and Supplementary Table 2 ). BRD4 is a member of the BET family of bromodomain proteins that bind acetylated histones 14, 15 . BRD4 has been implicated in several malignancies, including acute myeloid leukemia and lymphoma 16, 17 . BRD4 expression (mRNA and protein) increased with NOTCH1 inhibition and was higher in persister cells ( Fig. 2f and Supplementary Fig. 3f ).
This BRD4 dependency is of particular interest given the development of small molecule BET inhibitors, such as JQ1 (refs. 18,19) . Indeed, we found that persister cells exhibited ~5-fold enhanced sensitivity to JQ1 and underwent proliferation arrest and apoptosis in response to JQ1 concentrations that were well tolerated by naive T-ALL cells ( Fig. 2g and Supplementary  Figs. 2e and 4c) . We therefore considered whether the preexisting GSI-tolerant cells, identified in naive T-ALL populations by single-cell analysis (Fig. 1g) , might also be BRD4 dependent. Indeed, when we pretreated naive T-ALL cells with JQ1 for 4 d and then removed the JQ1 immediately before isolating individual cells into 96-well plates, the frequency of GSI-tolerant single cells was reduced by ~20-fold (Fig. 2h) . However, when we pretreated naive cells but then removed JQ1 24 h before isolating individual cells, we were able to detect GSI-tolerant l e t t e r s clones in a proportion similar to that found in control naive T-ALL cells. Thus, pre-existing GSI-tolerant cells in naive T-ALL populations are highly BRD4 dependent, like persister cells, and exist in dynamic equilibrium with the more prevalent GSI-sensitive cells.
To investigate its regulatory functions, we mapped BRD4 binding in naive and persister T-ALL populations by chromatin immunoprecipitation and sequencing (ChIP-seq). We also mapped histone modifications associated with promoters (trimethylation of histone H3 at lysine 4, H3K4me3), transcripts (trimethylation of histone H3 at lysine 36, H3K36me3), enhancers (monomethylation of histone H3 at lysine 4, H3K4me1 and acetylation of histone H3 at lysine 27, H3K27ac) and Polycomb-repressed loci (trimethylation of histone H3 at lysine 27, H3K27me3) 20, 21 . In both cell states, BRD4 bound promoters (~30% of sites) and putative enhancers enriched for H3K4me1 and H3K27ac marks (~60%) (Fig. 3a,b and Supplementary Fig. 5a ). We collated the largest BRD4 binding sites in persister cells, as these might reflect 'superenhancers' with critical functions in cell type-specific gene regulation 22 . Proximal genes encoded many known T-ALL regulators, including the transcription factor ETV6, the cell cycle regulator CDK6, the signaling molecule RPTOR and the prosurvival protein BCL2 (Fig. 3b-d, Supplementary Fig. 5b,d and Supplementary Table 3) . Although most large BRD4 peaks were shared by the populations, some were specific to either naive cells (for example, those in NOTCH1 target loci) or persister cells (Supplementary Fig. 5c ). Thus, BRD4 binds and may sustain the activity of the regulatory elements and target genes required for the proliferation of T-ALL cells.
We next considered the molecular basis for the preferential BRD4 dependency in persister cells. The relatively consistent BRD4 binding patterns in naive and persister cells suggest that BRD4 relocalization is unlikely to explain the different dependencies of these cells. However, persister cells exhibited an altered chromatin environment with greater npg l e t t e r s compaction, higher levels of repressive histone modifications and lower levels of the enhancer-associated H3K27ac mark ( Fig. 2c and Supplementary Fig. 3c-e,g ). Consistently, ChIP-seq data showed that persister cells had modestly higher levels of repressive histone modifications in potential regulatory regions (Supplementary Fig. 3h ). BRD4 is believed to have an important role as a 'bookmark' of active regulatory elements, maintaining their chromatin state as cells progress through mitosis 15, 23 . Thus, we suggest that generalized chromatin repression in npg l e t t e r s persister cells renders enhancers particularly dependent on BRD4 for their epigenetic maintenance (Supplementary Fig. 6 ). We next focused on individual genes that might account for BRD4 dependency. BCL2 is an established BRD4-dependent gene in mixed-lineage leukemia 24 . BCL2 was near a top-ranked BRD4 binding site and was expressed at higher levels in persister cells (Fig. 3b,d,f and Supplementary Figs. 3i and 5d) . Treatment with JQ1 markedly reduced BCL2 protein expression in persister cells but had little effect on its expression in naive cells (Fig. 3f) . Downregulation of BCL2 expression appears to contribute to the reduced survival of JQ1-treated persister cells, as exogenous BCL2 overexpression partially rescued these cells from JQ1 treatment (Figs. 2g and 3g) . The MYC oncogene is an established driver in T-ALL and represents a canonical BRD4 target 18 . A large enhancer in the MYC locus was strongly enriched for BRD4 binding ( Fig. 3e and Supplementary Fig. 5f ). Treatment with JQ1 noticeably reduced MYC protein expression in persister cells at doses that did not alter MYC expression in naive cells (Fig. 3f) . This effect could partially be rescued by MYC overexpression (Fig. 3h) . Hence, compromised survival of JQ1-treated persister cells depends on the downregulation of BCL2 and MYC.
To investigate the in vivo relevance of GSI resistance and associated epigenetic changes, we injected luciferase-expressing KOPT-K1 T-ALL cells orthotopically into NOD-scid IL2Rg null (NSG) mice and followed bioluminescence over time. GSI resistance developed rapidly in vivo after a short period of slowed leukemic growth (Supplementary Fig. 7a ). ICN1 levels were drastically reduced in the bone marrow of GSI-treated mice, and expression of NOTCH1 target genes was downregulated in the leukemia cells, indicating that resistance is not due to NOTCH1 reactivation (Fig. 4a,b) . These in vivo persister cells also shared other phenotypic characteristics with their in vitro counterparts, including reactivation of MYC expression and increased levels of CBX3 mRNA (encoding HP1γ) and BCL2 (Fig. 4a,c) .
We hypothesized that combined inhibition of NOTCH1 and BRD4 might be an effective treatment for T-ALL, including relapsed or induction failure disease, where conventional therapy has failed. We therefore examined the efficacy of GSI-JQ1 combination therapy in primary T-ALLs in vitro and in vivo. We examined three tumors from pediatric patients collected at diagnosis or upon relapse ( Supplementary Fig. 7b and Supplementary Table 4) , including a sample isolated from an individual with relapsed early thymic progenitor (ETP) T-ALL, who failed to respond to cytotoxic therapy. First, we examined the sensitivity of these leukemias to GSI, JQ1 or combined treatment in vitro. We found that the combination treatment was significantly more effective at inhibiting cell growth and survival than single-agent treatment (Fig. 4d) . To examine effects in vivo, we engrafted NSG mice with the primary T-ALLs and initiated treatment when a leukemic burden of ~25% in peripheral blood was reached. Randomized groups were treated with vehicle, NOTCH inhibitor (DBZ), BRD4 inhibitor (JQ1) or the DBZ-JQ1 combination for 3 weeks, and the effects on overall survival were determined (Fig. 4e,f) . Combination therapy significantly prolonged survival compared to treatment with vehicle or single-agent therapy for all three T-ALLs (Fig. 4f and Supplementary  Table 4) . Notably, primary leukemia cells treated with a single GSI agent in vivo had higher H3K27me3 levels, analogous to the lines treated in vitro (Supplementary Fig. 7c ). These data support the in vivo relevance of our study and the potential of this combination of targeted therapies to augment current and emerging therapies for T-ALL.
Therapeutic resistance plagued early GSI trials in humans 5 and is a major challenge in cancer treatment, pertinent to conventional chemotherapy and targeted therapy 25 . We have shown that T-ALLs can acquire GSI resistance by a fully reversible epigenetic mechanism. Persister cells rely on alternative signaling pathways to proliferate in the absence of NOTCH1 signaling and appear to arise from rare drug-tolerant cells already present in naive T-ALL populations. Persister cells also exhibit an altered chromatin state and enhanced sensitivity to BRD4 inhibition. Although the chromatin changes are reminiscent of an established model of drug-tolerant lung cancer cells 26 , the underlying mechanisms appear to be distinct, as we do not observe upregulation of KDM5A expression or sensitivity to histone deacetylase inhibitors (Supplementary Figs. 1f  and 2e) . The in vivo relevance of our findings is supported by the efficacy of combinatorial therapy with NOTCH and BRD4 inhibitors in patient-derived xenograft models of pediatric T-ALL. The effect of combination therapy in vivo is particularly striking given the short duration of treatment, the fact that treatment was initiated upon reaching a substantial leukemic burden and the refractory nature of the relapsed samples examined. Our study provides a framework for understanding epigenetic alterations and heterogeneity in tumor pathogenesis and suggests that drug resistance may be addressed by combination therapies that incorporate epigenetic modulators.
MeTHODS
Methods and any associated references are available in the online version of the paper. 
ONLINe MeTHODS
Cell culture. The human T cell leukemia cell lines DND-41 and KOPT-K1 were a kind gift of A.T. Look (Dana-Farber Cancer Institute). Cells were grown in RPMI-1640 containing 10% FCS at 37 °C with 5% CO 2 , tested for mycoplasma at regular intervals and maintained at a density of between 5 × 10 5 and 2 × 10 6 cells/ml. Persister cells were established by treating DND-41 or KOPT-K1 cells with 1 µM GSI for at least 7 weeks, replenishing the inhibitor every 3-4 d (Compound E, EMD4 Biosciences). Reversed cells were generated from persister cells by culturing without GSI for a minimum of 2 weeks. Cell numbers were determined using the Nexcelom Bioscience Cellometer Auto T4. Single cells were sorted into 96-well round-bottom plates and continuously treated with 1 µM Compound E or control. The number of clones that grew out after 4-6 weeks of culture was determined using a Zeiss Observer.Z1 with AxioCam MRm with a 2.5× objective imaging system. At least 500 wells were analyzed per condition in 2 independent experiments. Primary T-ALL cells obtained from pediatric patients with T-ALL with institutional review board (IRB) approval were passaged through NOD-scid IL2Rg null (NSG) mice and maintained in MEMα containing 10% FCS, 10% heatinactivated human AB+ serum, 10 ng/ml human interleukin (IL)-7, 50 ng/ml human stem cell factor (SCF), 20 ng/ml human FLT3 ligand, 20 nM insulin and 100 ng/ml IL-2 at 37 °C with 5% CO 2 .
Cell proliferation and apoptosis assays. Viable T-ALL cell lines were plated in 2-4 replicates in black or white opaque flat-bottom 96-well tissue culture plates. For proliferation assays, cells were titrated to allow log-phase growth for a period of 4 to 9 d before readout (5,000 to 15,000 cells per well). Viable primary T-ALL cells were plated in 2-3 replicates in black opaque flat-bottom 96-well tissue culture plates at 50,000-100,000 cells per well and were cultured for 6 d. Cell proliferation was measured using the CellTiter-Glo Luminescent Cell Viability Assay from Promega as described by the manufacturer. Apoptosis was measured as a function of caspase 3 and caspase 7 cleavage using the Caspase-Glo 3/7 Luminescent Assay from Promega as described by the manufacturer. End-point luminescence was measured on a SpectraMax M5 plate reader (Molecular Diagnostics). Statistical analyses were performed using Student's t tests, assuming equal variance. A two-sided P value of <0.05 was considered to indicate statistical significance. Error bars reflect s.d.
In vitro inhibitor assays, protein blots and ELISAs. GSI (Compound E) was obtained from EMD4 Biosciences. Rapamycin and the AKT inhibitor MK-2206 were purchased from Selleck Chemicals. Stock aliquots (1-100 mM) were prepared in DMSO (Sigma-Aldrich) and diluted in appropriate medium before use. Matching DMSO concentrations were used for control treatment. For protein blots, cells were collected after treatment and processed as described previously 27 . Total protein amount in each sample was determined using the SDS-compatible Bio-Rad DC Protein Assay. Membranes were developed using Amersham ECL Plus Western Blotting Detection Reagents (GE Healthcare, Life Sciences) and visualized using photographic film. Protein blots used antibodies against α-tubulin (ab7291), BCL2 (ab18210), BRD4 (ab75898) and total histone H3 (ab1791), all from Abcam; cleaved NOTCH1 (ICN1; 4147), total mTOR (5536), phospho-mTOR 2481 (9964), total PTEN (9552), phospho-PTEN (9551) and HP1γ (2616), all from Cell Signaling Technology; MYC from Cell Signaling Technology (9402) and Santa Cruz Biotechnology (sc-764); H3K27ac from ActiveMotif (39133); and β-actin from Sigma (A5441). All primary antibodies were used at 1:1,000 dilutions, except for the antibodies to α-tubulin (1:10,000 dilution), β-actin (1:5,000 dilution) and total histone H3 (1:25,000 dilution). Histone ELISAs for H3K27me3, H3K9me3 and total histone H3 were obtained from ActiveMotif. Signal for H3K27me3 and H3K9me3 for each sample was determined as a fraction of total histone H3, following the protocol described by the manufacturer. Statistical analyses were performed using Student's t tests, assuming equal variance. A two-sided P value of <0.05 was considered to indicate statistical significance. Error bars reflect s.d.
Quantitative RT-PCR analyses. Total RNA was extracted with the RNeasy Mini kit (Qiagen) and reverse transcribed into cDNA using the SuperScript III First-Strand Synthesis system for RT-PCR. qPCR was performed with FastStart Universal SYBR Green Master (Roche) on an ABI 7500 (primer sequences are listed in Supplementary Table 5 ). Gene expression was measured by determining the log 2 (C t ) value of the desired transcript compared to either GAPDH or B2M (encoding β2-microglobulin) transcript. Statistical analyses were performed using Student's t tests, assuming equal variance. A two-sided P value of <0.05 was considered to indicate statistical significance. Error bars reflect s.d.
Flow cytometry and cell sorting. Flow cytometric analysis and sorting were performed on a BD FACSCalibur or BD LSR II (analysis) and BD FACSAriaII or MoFLo (sorting), using FITC-, PE-and APC-conjugated antibodies against CD45 (2.5 µl) and BCL2 (5 µl) and appropriate isotype controls (all from BD Pharmingen). Intracellular staining was performed according to the manufacturer's instructions. For flow cytometric analysis of spleens, single-cell solutions were generated, and red blood cell lysis was performed before staining. Cell sorting for CD45-positive and mCherry-positive cells was carried out on a FACSAria II. Single cells were sorted into 96-well roundbottom plates using the FACSAria II.
DAPI staining. For DAPI staining, 5 × 10 7 cells were fixed in 4% paraformaldehyde (PFA) in PBS and permeabilized with 1% Triton X-100. Cells were mounted on slides using Vectashield mounting medium with 1.5 µg/ml DAPI (Vector Laboratories). Slides were imaged on an Olympus IX51 microscope with a QCapture ×65 camera (400×) and QImaging software. Nuclear size was quantified using ImageJ software.
MNase digestion.
Mononucleosome isolation was performed as described with modifications 28 . Naive and persister cells were incubated with 0.5% Triton X-100 in buffer 1 (10 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.5, 10 mM sodium butyrate, 60 mM KCl, 15 mM NaCl, 5 mM MgCl 2 , 0.25 M sucrose) on ice. Nuclei were then layered onto 2.5 volumes of 30% sucrose in buffer 1 and centrifuged at 3,720g. Purified nuclei were resuspended in buffer 2 (20 mM HEPES, pH 7.8, 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 10% glycerol, 2 mM CaCl 2 , 1 mM dithiothreitol) with 200 U of micrococcal nuclease (Roche Diagnostics) at room temperature for 5 min, 10 min or 15 min, and reactions were then quenched by the addition of EGTA to a final concentration of 1 mM. Digested DNA was phenol-chloroform extracted and run on an agarose gel.
Chromatin immunoprecipitation assays.
We performed ChIP-qPCR and ChIP-seq analysis in naive and persister DND-41 and KOPT-K1 cells as described 27 . Chromatin from formaldehyde-fixed cells (1-5 × 10 6 cells per histone mark, 1 × 10 7 cells for BRD4 binding) was fragmented to a size range of 200-700 bases with a Branson 250 Sonifier. Solubilized chromatin was immunoprecipitated with antibody against H3K4me3 (Millipore, 07-473CA), H3K36me3 (Abcam, ab9050), H3K27me3 (Millipore, 07-449), H3K27ac (ActiveMotif, ab4729), H3K4me1 (Abcam, ab8895) and BRD4 (Bethyl, A301-985A), using 2.5 µl for H3K36me3, H3K4me3 and H3K27ac; 5 µl for H3K4me1 and H3K27me3; and 10 µl for BRD4. Each of these antibodies was validated by protein blot and dot blot as described 29 . Antibody-chromatin complexes were pulled down with Protein A-Sepharose, washed and then eluted. After cross-link reversal and proteinase K treatment, immunoprecipitated DNA was extracted with phenol-chloroform, precipitated with ethanol and treated with RNase. ChIP DNA was quantified with PicoGreen.
ChIP enrichments were assessed by qPCR analysis on an ABI 7500 with 0.2 ng of ChIP DNA and an equal amount of unenriched input DNA (whole-cell extract and background control). Enrichment was calculated by determining the log 2 (C t ) value for the ChIP DNA relative to that of the whole-cell extract. Primer sequences are listed in Supplementary Table 5 .
For ChIP-seq, libraries were prepared according to Illumina's instructions. ChIP DNA and input controls were sequenced with the HiSeq Illumina Genome Analyzer. ChIP-seq reads were aligned to the reference genome (hg19) using SOAP2 (ref. 30 ), allowing at most two mismatches. Positions were randomly selected for reads with multiple hits. Reads aligned to the same position and strand were only counted once. We extended aligned reads by 250 bp to approximate fragment sizes and then derived a 25-bp resolution density map by counting the number of fragments overlapping each position. We calculated H3K27me3 density across 10-kb regions centered on distal elements marked by H3K4me1 only to analyze the local dynamics of H3K27me3 modification and normalized enrichment to the background level as described 31 .
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